Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.35 |
| ▸ | PTGFR | P43088 | 1/20 | 0.35 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 5/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 8/20 | 0.34 |
| ▸ | PPARD | Q03181 | 7/20 | 0.34 |
| ▸ | PPARA | Q07869 | 7/20 | 0.34 |
| ▸ | TK1 | P04183 | 1/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.33 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.33 |
| ▸ | TLR2 | O60603 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | FABP4 | P15090 | 2/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.33 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.33 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30465016 | 1.00 | ALDH1A1 (0.41) | ALDH1A1TBXA2RPTGFRPTGER2TSHR | |
| SCHEMBL30465046 | 1.00 | ALDH1A1 (0.41) | ALDH1A1TBXA2RPTGFRPTGER2TSHR | |
| SCHEMBL29779646 | 1.00 | ALDH1A1 (0.41) | ALDH1A1TBXA2RPTGFRPTGER2TSHR | |
| SCHEMBL16084870 | 1.00 | ALDH1A1 (0.41) | ALDH1A1TBXA2RPTGFRPTGER2TSHR | |
| SCHEMBL30465062 | 1.00 | ALDH1A1 (0.41) | ALDH1A1TBXA2RPTGFRPTGER2TSHR | |
| SCHEMBL24721233 | 1.00 | ALDH1A1 (0.41) | ALDH1A1TBXA2RPTGFRPTGER2TSHR | |
| SCHEMBL16145439 | 1.00 | ALDH1A1 (0.41) | ALDH1A1TBXA2RPTGFRPTGER2TSHR | |
| SCHEMBL16154509 | 1.00 | ALDH1A1 (0.41) | ALDH1A1TBXA2RPTGFRPTGER2TSHR | |
| SCHEMBL30465054 | 1.00 | ALDH1A1 (0.41) | ALDH1A1TBXA2RPTGFRPTGER2TSHR | |
| SCHEMBL30465037 | 1.00 | ALDH1A1 (0.41) | ALDH1A1TBXA2RPTGFRPTGER2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4742895-A2 | ASCAROSIDES AND INSECTICIDE COMBINATIONS AND METHODS FOR USE | Ascribe Bioscience Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-4735460-A2 | ASCAROSIDES AND HERBICIDAL COMBINATIONS AND METHODS FOR USE | Ascribe Bioscience Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4723893-A2 | COMPOSITIONS AND METHODS TO MITIGATE PHYTOTOXIC EFFECTS OF AGRICHEMICALS | Ascribe Bioscience Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| WO-2025226798-A1 | MODIFIED ASCAROSIDES | Ascribe Bioscience Inc. (US) | 2025-10-30 | — | — | WO | disclosed |
| US-20250287946-A1 | MODIFIED RELEASE OF ASCAROSIDES | Ascribe Bioscience Inc. | 2025-09-18 | — | — | US | disclosed |
| EP-4529418-A1 | ASCAROSIDE COMBINATIONS | Ascribe Bioscience Inc. (US) | 2025-04-02 | — | — | EP | disclosed |
| CN-119731187-A | Ascaroside salt | 归因生物科技有限公司 | 2025-03-28 | — | — | CN | disclosed |
| EP-4522627-A1 | ASCAROSIDE SALTS | Ascribe Bioscience Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| CN-119630286-A | Modified release of ascaroside | 归因生物科技有限公司 | 2025-03-14 | — | — | CN | disclosed |
| EP-4514131-A1 | MODIFIED RELEASE OF ASCAROSIDES | Ascribe Bioscience Inc. (US) | 2025-03-05 | — | — | EP | disclosed |
| EP-4447680-A1 | METHODS OF SEED AND PLANT TREATMENT TO REDUCE FOODBORNE ILLNESS | Ascribe Bioscience Inc. (US) | 2024-10-23 | — | — | EP | disclosed |
| CN-118742205-A | Seed and plant treatment methods for reducing food-borne diseases | 归因生物科技有限公司 | 2024-10-01 | — | — | CN | disclosed |
| WO-2024178020-A2 | ASCAROSIDE DERIVATIVES | Ascribe Bioscience Inc. (US) | 2024-08-29 | — | — | WO | disclosed |
| WO-2023230092-A1 | ASCAROSIDE COMBINATIONS | Ascribe Bioscience Inc. (US) | 2023-11-30 | — | — | WO | disclosed |
| WO-2023220174-A1 | ASCAROSIDE SALTS | Ascribe Bioscience Inc. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023212362-A1 | MODIFIED RELEASE OF ASCAROSIDES | Ascribe Bioscience Inc. (US) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023196636-A1 | METHODS OF TREATING PLANT-BASED PRODUCTS TO REDUCE MICROBE PROLIFERATION AND EXTEND SHELF LIFE | Ascribe Bioscience Inc. (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023115054-A1 | METHODS OF SEED AND PLANT TREATMENT TO REDUCE FOODBORNE ILLNESS | ASCRIBE BIOSCIENCE (US) | 2023-06-22 | — | — | WO | disclosed |
| US-20220409650-A1 | COMPOSITIONS AND METHODS FOR ASCAROSIDE MODIFICATION OF MAMMALIAN MICROBIOTA | HOLOCLARA INC (US) | 2022-12-29 | — | — | US | disclosed |
| US-20220248672-A1 | COMPOSITIONS AND METHODS FOR MODULATING MICROBIOMES | BOYCE THOMPSON INSTITUTE FOR PLANT RESEARCH, INC. | 2022-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220248672-A1 | COMPOSITIONS AND METHODS FOR MODULATING MICROBIOMES | VIP, FABP2, FBL | ALDH1A1 2756/4885TBXA2R 1368/4885PTGFR 2771/4885 |
| US-20250287946-A1 | MODIFIED RELEASE OF ASCAROSIDES | ABCC1, NLRP3, NOD1 | ALDH1A1 1844/4885TBXA2R 3135/4885PTGFR 4872/4885 |
| US-20220409650-A1 | COMPOSITIONS AND METHODS FOR ASCAROSIDE MODIFICATION OF MAMMALIAN MICROBIOTA | SI, FABP2, ALPI | ALDH1A1 1040/4885TBXA2R 4319/4885PTGFR 4845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.